In recent studies, it was shown that elevated serum concentrations of osteopontin are associated with the increased occurrence of exacerbation in pulmonary fibrosis patients, and, as a result, higher mortality compared to patients with low osteopontin-serum concentrations and stable pulmonary fibrosis [379] (Table 3). The gene discussed is SPP1; the disease is pulmonary fibrosis.